BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17786406)

  • 21. The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors.
    Andressen KW; Manfra O; Brevik CH; Ulsund AH; Vanhoenacker P; Levy FO; Krobert KA
    Br J Pharmacol; 2015 Aug; 172(15):3846-60. PubMed ID: 25884989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
    Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
    Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors.
    Thomas DR; Middlemiss DN; Taylor SG; Nelson P; Brown AM
    Br J Pharmacol; 1999 Sep; 128(1):158-64. PubMed ID: 10498847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
    Newman-Tancredi A; Verrièle L; Millan MJ
    Br J Pharmacol; 2001 Jan; 132(2):518-24. PubMed ID: 11159702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine effects on adenylyl cyclase activity and serotonin type 1A receptors in human brain post-mortem.
    Marazziti D; Baroni S; Palego L; Betti L; Giannaccini G; Castagna M; Naccarato AG; Luccachini A; Catena-Dell'Osso M; Dell'Osso L
    J Psychopharmacol; 2014 Apr; 28(4):320-8. PubMed ID: 24429224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
    Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.
    Thomas DR; Gittins SA; Collin LL; Middlemiss DN; Riley G; Hagan J; Gloger I; Ellis CE; Forbes IT; Brown AM
    Br J Pharmacol; 1998 Jul; 124(6):1300-6. PubMed ID: 9720804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.
    Krobert KA; Levy FO
    Br J Pharmacol; 2002 Mar; 135(6):1563-71. PubMed ID: 11906971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.
    Ueda T; Ugawa S; Ishida Y; Shimada S
    Eur J Pharmacol; 2011 Dec; 671(1-3):79-86. PubMed ID: 21951966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
    Newman-Tancredi A; Verrièle L; Touzard M; Millan MJ
    Eur J Pharmacol; 2001 Oct; 428(2):177-84. PubMed ID: 11675034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.